Investments (Schedule Of Fair Value Method Investments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Cash and cash equivalents	$ 44,167	$ 109,403	$ 44,167	$ 109,403	$ 68,939	$ 73,191
Other tangible assets	67,290		67,290		54,041
Total assets	737,881		737,881		780,610
Total liabilities and shareholders' equity	737,881		737,881		780,610
Revenues	221,748	203,924	660,274	597,037
Expenses and other, net	(202,560)	(191,321)	(619,080)	(565,256)
Income tax (expense) benefit	(4,661)	133	(11,516)	(6,329)
Net income	7,427	12,736	17,778	25,107
Specialty Pharmaceutical Company [Member]
Cash and cash equivalents	20,483		20,483		9,625
Other Assets, Current	3,824		3,824		4,894
Other tangible assets	2,041		2,041		691
Identifiable intangible assets	1,988		1,988		1,868
Total assets	28,336		28,336		17,078
Other current liabilities	1,960		1,960		1,185
Non-current liabilities	15,945		15,945		738
Redeemable preferred stock	20,749		20,749		20,017
Other	(10,318)		(10,318)		(4,862)
Total liabilities and shareholders' equity	28,336		28,336		17,078
Revenues		2,255		8,839
Expenses and other, net	(3,089)	(2,569)	(8,026)	(8,235)
Income tax (expense) benefit	1,209	112	3,100	(181)
Net income	$ (1,880)	$ (202)	$ (4,926)	$ 423